arrow
J

John Nemunaitis

gradalis inc
H指数:92
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product

外显子组测序显示自体肿瘤和Vigil产物之间的克隆肿瘤突变负荷,肿瘤内异质性和克隆新抗原的相同模式

2025-03-131
OAAI
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

Vigil/替莫唑胺/伊立替康治疗复发性尤因肉瘤的初步研究和循环肿瘤 (ct) DNA的评估

2023-02-138
OAAI
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

ENTPD1/CD39作为新诊断卵巢癌维持治疗对吉非替尼治疗反应的预测指标

2022-08-2911
OA
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

探索伊塔替尼联合epacadostat或parsaclisib治疗晚期实体瘤的安全性,对肿瘤微环境的影响和疗效: 一期研究

2022-03-1412
OAAI
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

Pembrolizumab联合Acalabrutinib治疗晚期头颈部鳞状细胞癌的安全性和有效性: 2期概念验证研究

2021-12-0218
OAAI